Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: VeraLight, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Hyperglycemia
Interventions: Not listed
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Metastatic Cancer Pancreas
Interventions: PF-03084014, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Aurora, Colorado • Rochester, New York

Conditions: Type 1 Diabetes, Hyperglycemia, Postprandial
Interventions: Insulin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Diabetes Mellitus
Interventions: FK614; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 36
States / cities: Ozark, Alabama • Tucson, Arizona • Cypress, California + 29 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle, BD NEXT 32G x 4mm pen needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Toms River, New Jersey • Asheville, North Carolina • Kingsport, Tennessee + 1 more

Conditions: Diabetes Mellitus Type II, Hypertension
Interventions: Integrated CHW Intervention, CHW Session 1 Only; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Interventions: Cisplatin, No treatment; Drug · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 59
States / cities: Duarte, California • La Jolla, California • Newport Beach, California + 43 more

Conditions: Weight Loss, Postpartum Weight Retention, Hypertension in Pregnancy, Diabetes Mellitus in Pregnancy, Preeclampsia, Recruitment
Interventions: Online Behavioral Weight Loss Program, Virtual weigh-in; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Adenocarcinoma
Interventions: Temsirolimus, Gemcitabine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Cancer, Pancreas Cancer, Pain
Interventions: Celiac Plexus Radiosurgery; Radiation
Lead sponsor: Dr. Yaacov Lawrence; Government
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: New York, New York • Columbus, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Sensor-augmented pump (SAP); Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Diabetic Neuropathies
Interventions: Fish Oil Concentrate, 1000 Mg Oral Capsule, Salsalate Oral Tablet; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Portland, Oregon

Conditions: Diabetes Mellitus, Type 2
Interventions: SGLT2, Metformin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cushings Disease
Interventions: R-roscovitine; Drug
Lead sponsor: Shlomo Melmed, MD; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy, Neuropathic Pain, Chronic Pain
Interventions: BurstDR Spinal Cord Stimulation; Device
Lead sponsor: TriCity Research Center; Industry
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Grand Island, Nebraska

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
Interventions: ATX-295, ATX-295 and bevacizumab (or biosimilar); Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more

Conditions: Epithelial Ovarian Cancer
Interventions: Seprafilm™; Procedure
Lead sponsor: University of British Columbia; Other
Eligibility: Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes Mellitus
Interventions: Glargine, glargine via insulin pen; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 60 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diabetic Polyneuropathy
Interventions: ANS Eon™ Implantable Pulse Generator (Permanent Implant), Placebo; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Type 1 Diabetes
Interventions: Adherence behaviors and recommendations for improvement., Adherence behavior that needs improvement is targeted; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: PreDiabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Body Weight, Body Weight Changes
Interventions: DiRECT, Usual care (UC); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Bias Source of Signal in SCOUT DS

Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes

Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

Clinical Evaluation of BD NEXT Pen Needle

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Postpartum Weight Loss for Women at Elevated Cardiovascular Risk

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Celiac Plexus Radio-Surgery for Pain Management

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Treatment of Cushing's Disease With R-roscovitine

Efficacy and Feasibility of BurstDR SCS in Painful Diabetic Neuropathy

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Spinal Cord Stimulation for Diabetic Polyneuropathy

Adherence Intervention to Promote Optimal Use of Insulin Pumps in Adolescents With Type 1 Diabetes

Diabetes Risk Education and Communication Trial